Refine by
Therapeutic Vaccine Technology
29 companies found
Technologybased inPhiladelphia, PENNSYLVANIA (USA)
Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics and vaccines to bring more effective gene therapies and personalized medicines to patients. We are developing a compelling portfolio of innovative and personalized saRNA-based ...
Self-amplifying RNA (saRNA) replicon is a type of RNA genome that is unique to certain families of viruses. This highly specialized system lets the virus make multiple copies of its RNA genome, and therefore encoded proteins, from just a single RNA ...
Technologybased inOxford, UNITED KINGDOM
Utilising unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide. SpyBiotech came into being to change that. Our pioneering technology, the proprietary protein superglue SpyTag/SpyCatcher, enables us ...
Technologybased inBogotá, COLORADO (USA)
At Integra IT, we’re on a mission to expand clinical research possibilities worldwide, especially in diversity, inclusion, and emerging countries. Our comprehensive software ecosystem is cost-convenient and high-efficient for all clinical research ...
Technologybased inSan Diego, CALIFORNIA (USA)
Ichor Medical Systems Inc., a privately-held biotech company founded in San Diego in 1994, is developing products based on the in vivo application of electroporation to enhance intracellular delivery of nucleic acid-based drugs encoding therapeutic ...
Technologybased inAalborg Øst, DENMARK
2A Pharma is a clinical stage Swedish/Danish biopharmaceutical company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented AAVLP platform. To develop novel, cost ...
Technologybased inIllkirch-Graffenstaden, FRANCE
Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for ...
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
Technologybased inVancouver, BRITISH COLUMBIA (CANADA)
Precision NanoSystems is a global leader in technologies, solutions and services for the development of non-viral delivery of genomic medicines, including mRNA vaccines and therapeutics. We work with the world’s leading drug developers to understand ...
Technologybased inMerelbeke, BELGIUM
Ziphius Vaccines is named after the rare dolphin Ziphius cavirostris. This dolphin is most known for undertaking the deepest and longest dives recorded. Ziphius' mission is to reduce the global impact of infectious diseases on global health care by ...
Technologybased inNiel, BELGIUM
eTheRNA has developed a proprietary and integrated set of platform technologies that are overcoming the challenges facing the development of next generation mRNA therapeutics. Our platform includes mRNA construct design and optimization, proprietary ...
Therapeutic area: cancer vaccines; Systemic, intravenous (IV) ...
Technologybased inBaldham, GERMANY
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ...
Several cancers arise from the lack of DNA mismatch repair (MMR) resulting in the accumulation of thousands of single deletions or insertions at coding microsatellites (MSI-H). These mutations lead to the inactivation of specific proteins and to the ...
Technologybased inCambridge, MASSACHUSETTS (USA)
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP ...
When properly stimulated, the human immune system is incredibly powerful and has profound potential. Because of their structural similarity to viruses presented in nature, including their particulate nature and repetitive structure, virus-like ...
Technologybased inBreitenfurt, AUSTRIA
Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology ...
Lead candidate TYG100 (formerly OQR100, out-licensed to TYG oncology Ltd.) is an “Active Checkpoint Control Immunotherapy (ACCI)” for the treatment of gastroenterological cancers such as pancreatic, stomach, colon, and gastro-esophageal ...
Technologybased inAddison, TEXAS (USA)
VITRUVIAN BioMedical, Inc is a biotechnology company focused on a unique Business Strategy based on Early, Medium and Late Stage product development. We are committed to providing 'Advance Personalized Medicine' to medical professionals and patients ...
VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine for the Prevention of Alzheimer's Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global ...
Technologybased inMölndal, SWEDEN
Alzinova AB is a Swedish clinical-stage biopharma company pioneering the development of an active immunotherapy against Alzheimer’s disease. The vaccine is in clinical development and tested in patients. The company’s shares (ALZ) are listed on ...
Technologybased inRixensart, BELGIUM
CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines for the treatment of autoimmune diseases. The company was founded by a ...
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
Technologybased inParis, FRANCE
Oncovita is a biotech company developing a disruptive virus-derived vaccine technology to treat multiple types of cancers. Our MeasovirTM platform was developed based on the safe and highly immunogenic measles virus vaccine, a vaccine with ...
Technologybased inActon, AUSTRALIA
Lipotek is a developer of targeted vaccine delivery and adjuvant technologies. There is an undeniable need for technological solutions for prophylactic and therapeutic vaccination against pathogens, cancer and other diseases that have limited or no ...
Technologybased inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first ...
Technologybased inNanjing, CHINA
Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, ...
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically ...
Technologybased inElkridge, MARYLAND (USA)
Latham BioPharm Group (LBG) is a leading life sciences consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies alike to solve complex business, regulatory, and product development ...
Strategic regulatory planning and implementation is a critical component of any product development program. Understanding the regulatory pathway up front not only allows for clarity in the development process but can also save valuable time and ...